Clinical trials: High Risk Group of Schizophrenia
Negative Symptoms of Schizophrenia
SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms…
- Trial name
- NSS (NCT01234298)
- Testing
- SPD489 Low-Dose, SPD489 High-Dose
- Sponsor
- Shire
Schizophrenia
A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study
This is a prospective, six-week, randomized, double blind, placebo-controlled, multi-center study in patients with schizophrenia who are experiencing an acute exacerbation of psychosis.
- Trial name
- NCT00567710
- Testing
- BL - 1020, Risperidone
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To Risperidone, In Schizophrenic Patients Previously…
- Trial name
- NCT00722176
- Testing
- BL-1020, BL-1020 10-30 mg, risperidone
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire